1. 2007
2. Published

   Quantitative risk-benefit analysis

   Hughes, D. & Hughes, D. A., 1 May 2007.

   Research output: Contribution to conference › Paper

3. Published

   What determines which interventions improve compliance, and do they improve health outcomes in a cost-effective manner?

   Hughes, D., Hughes, D. A., LaFleur.*, N. V., Salas, M. & Shinogle, J., 1 May 2007.

   Research output: Contribution to conference › Paper

4. Published

   Adherence with HAART: pharmacoeconomic considerations

   Hughes, D. & Hughes, D. A., 1 Jun 2007.

   Research output: Contribution to conference › Paper

5. Published

   Adverse drug reactions in economic evaluations

   Hughes, D. & Hughes, D. A., 1 Jul 2007.

   Research output: Contribution to conference › Paper

6. Published

   A prototype agent-based model of antimalarial drug compliance

   Hughes, D., McKean, J., Rahlf, S., Shorter, H., Barnish, G., Paton, R., McBurney, P., Hughes, D. A. & Hastings, I., 1 Aug 2007.

   Research output: Contribution to conference › Paper

7. Published

   Cost of non-compliance and non-persistence with medications for diabetes mellitus

   Hughes, D., Salas, M., Hughes, D. A., Lebmeier, M. & Vardeva, K., 1 Aug 2007.

   Research output: Contribution to conference › Paper

8. Published

   Current assessment of risk-benefit by regulators: Is it time to introduce decision analyses?

   Hughes, D., Hughes, D. A., Pirmohamed, M. & Bayoumi, A., 1 Aug 2007.

   Research output: Contribution to conference › Paper

9. Published

   Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?

   Hughes, D., Hughes, D. A., Bayoumi, A. M. & Pirmohamed, M., 1 Aug 2007, In: Clinical Pharmacology and Therapeutics. 82, 2, p. 123-127

   Research output: Contribution to journal › Article › peer-review

10. Published

    Impact of the abolition of prescription charges in Wales: a multi-level modelling approach with application to time series dispensed rate data

    Hughes, D., Alam, F., Myles, S., Hughes, D. A., Dunstan, F., Routledge, P. & Cohen, D., 1 Sept 2007.

    Research output: Contribution to conference › Paper

11. Published

    Feasibility, validity and reliability of the Welsh version of the EQ-5D health status questionnaire.

    Hughes, D. & Hughes, D. A., 1 Oct 2007, In: Quality of Life Research. 16, 8, p. 1419-1423

    Research output: Contribution to journal › Article › peer-review

12. Published

    Interventions that enhance medication compliance and persistence: Theoretical grounding, and economic assessment

    Hughes, D., Hughes, D. A., Gwadry Sridhar, F., Elliott, R. & Cowell, W., 1 Oct 2007.

    Research output: Contribution to conference › Paper

13. Published

    Pharmacoeconomic evaluations in Ireland, Scotland and Wales: A Celtic perspective on pharmaceutical assessment

    Hughes, D., Hughes, D. A., Drummond, M., Tolley, K. & Ryan, M., 1 Oct 2007.

    Research output: Contribution to conference › Paper

14. Published

    The assessment, determinants & economics of medication compliance & persistence

    Hughes, D., Hughes, D. A., Gwadry Sridhar, F. & Elliott, R., 1 Oct 2007.

    Research output: Contribution to conference › Paper

15. Published

    Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations.

    Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Nov 2007, In: Value in Health. 10, 6, p. 498-509

    Research output: Contribution to journal › Article › peer-review

16. Published

    Orphan drug treatments: economic considerations

    Hughes, D. & Hughes, D. A., 1 Nov 2007.

    Research output: Contribution to conference › Paper

17. Published

    Population pharmacokinetics of warfarin: Intermin analysis of the Liverpool pharmacogenetic prospective cohort study

    Hughes, D., Matthews, I., Aarons, L., Al-Zubiedi, S., Hatch, E., Lane, S., Williamson, P., Kamali, F., Hughes, D. A. & Pirmohamed, M., 1 Nov 2007.

    Research output: Contribution to conference › Paper

18. Published

    The effect of compliance upon clinical effectiveness of chlorproguanil-dapsone (CD) and artemether-lumefantrine (AL) when compared to sulfadoxine-pyrimethamine (SP) for the treatment of uncomplicated falcipaum malaria in Malawi - a randomised controlled trial

    Hughes, D., Bell, D. J., Wootton, D., Mukaka, M., Montgomery, J., Kayange, N., Chimpeni, P., Zijlstra, E., Hughes D.A., N. V., Molyneux M.E.*, N. V., Ward, S. A., Winstanley, P. A. & Lalloo, D. G., 1 Nov 2007.

    Research output: Contribution to conference › Paper

19. Published

    Folate Augmentation of Treatment – Evaluation for Depression (FolATED): protocol of a randomised controlled trial.

    Russell, I. T., Slegg, G. P., Roberts, S. H., Bedson, E., Hughes, D., Lloyd, K., Moat, S., Pirmohamed, M., Slegg, G., Tranter, R., Whitaker, R., Wilkinson, C. & Russell, I., 15 Nov 2007, In: BMC Psychiatry. 7, 1, p. 65

    Research output: Contribution to journal › Article › peer-review

20. Published

    A Global Survey of Antibiotic Leftovers in the Outpatient Setting.

    Hughes, D., Kardas, P., Pechere, J. C., Hughes, D. A. & Cornaglia, G., 1 Dec 2007, In: International Journal of Antimicrobial Agents. 30, 6, p. 530-536

    Research output: Contribution to journal › Article › peer-review

21. Published

    Public meetings of the NICE appraisals committee

    Hughes, D. & Hughes, D. A., 1 Dec 2007.

    Research output: Contribution to conference › Paper

22. Published

    The pharmacokinetic profile of Warfarn: a systematic review

    Hughes, D., Al-Zubiedi S.*, N. V., Hughes D.A., N. V. & Pirmohamed, M., 1 Dec 2007.

    Research output: Contribution to conference › Paper

23. 2008
24. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

25. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

26. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

27. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report